DiaSorin S.p.A (DSRLF PINK) stock market data APIs
$108.6579
0(0%)
as of March 26, 2025
DiaSorin S.p.A Financial Data Overview
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Prev. Close
108.6579
Open
108.6579
High
108.6579
Low
108.6579
52 wk Range
88.45-109.6
Market Cap
5 907 M
P/E Ratio
28.8421
Shares Outstanding
53 892 K
Revenue
1 185 M
Dividends (Yield)
0.0119
Beta
0.162
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get DiaSorin S.p.A data using free add-ons & libraries
Get DiaSorin S.p.A Fundamental Data
DiaSorin S.p.A Fundamental data includes:
- Net Revenue: 1 185 M
- EBITDA: 368 M
- Earnings Per Share: 3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
DiaSorin S.p.A News
New
Diasorin SpA (DSRLF) Full Year 2024 Earnings Call Highlights: Resilient Performance Amid Global ...
Release Date: March 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Diasorin SpA (DSRLF) reported revenue and profitabi...
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
Cytek Biosciences, Inc. Sale of assets related to Flow Cytometry & Imaging (FCI) Business Unit Acquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven...
BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes NEW YORK, May 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Announces Upcoming Scientific Conference Presentations
Data on MSC-NTF exosome technology at ISCT 2022 and ISEV 2022 conferences NurOwn® CFS biomarker analysis to be presented at ALS Drug Development Summit NEW YORK, May 3, 2022 /PRNewswire/ -- BrainSt...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
